BRPI0511900A - composições farmacêuticas - Google Patents

composições farmacêuticas

Info

Publication number: BRPI0511900A
Authority: BR; Brazil
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2004-06-08

Application number

BRPI0511900-6A

Other languages

English (en)

Inventor

Maura Murphy

Kirk Dinehart

Patricia Hurter

Patrick Connelly

Yong Cui

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-08

Filing date

2005-06-08

Publication date

2008-01-22

2005-06-08 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-01-22 Publication of BRPI0511900A publication Critical patent/BRPI0511900A/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Mechanical Treatment Of Semiconductor (AREA)

BRPI0511900-6A 2004-06-08 2005-06-08 composições farmacêuticas BRPI0511900A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57804304P	2004-06-08	2004-06-08
PCT/US2005/019929 WO2005123076A2 (en)	2004-06-08	2005-06-08	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
BRPI0511900A true BRPI0511900A (pt)	2008-01-22

Family

ID=35510250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0511900-6A BRPI0511900A (pt)	2004-06-08	2005-06-08	composições farmacêuticas

Country Status (18)

Country	Link
US (2)	US20060089385A1 (pt)
EP (1)	EP1765283A4 (pt)
JP (2)	JP2008501802A (pt)
KR (2)	KR20120039763A (pt)
CN (2)	CN1988885A (pt)
AR (1)	AR049297A1 (pt)
AU (1)	AU2005253957B2 (pt)
BR (1)	BRPI0511900A (pt)
CA (1)	CA2569310A1 (pt)
IL (2)	IL179809A (pt)
MX (1)	MXPA06014253A (pt)
NO (1)	NO20070130L (pt)
NZ (1)	NZ588471A (pt)
RU (1)	RU2373923C2 (pt)
SG (1)	SG153800A1 (pt)
TW (1)	TWI389688B (pt)
WO (1)	WO2005123076A2 (pt)
ZA (2)	ZA200700030B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69709671T2 (de) *	1996-10-18	2002-08-22	Vertex Pharmaceuticals Inc., Cambridge	Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
UY28500A1 (es) *	2003-09-05	2005-04-29	Vertex Pharma	Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TW201424733A (zh) *	2004-10-29	2014-07-01	Vertex Pharma	劑量型式
AR055198A1 (es)	2005-06-02	2007-08-08	Schering Corp	Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
EP1891089B1 (en)	2005-06-02	2014-11-05	Merck Sharp & Dohme Corp.	HCV protease inhibitors in combination with food
RU2441020C2 (ru) *	2005-08-02	2012-01-27	Вертекс Фармасьютикалз Инкорпорейтед	Ингибиторы серинпротеазы
US8399615B2 (en)	2005-08-19	2013-03-19	Vertex Pharmaceuticals Incorporated	Processes and intermediates
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en)	2005-08-26	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AU2007217355B2 (en) *	2006-02-27	2012-06-21	Vertex Pharmaceuticals Incorporated	Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
US20070207122A1 (en) *	2006-03-06	2007-09-06	Kempf Dale J	Compositons and methods of use of ritonavir for treating hcv
WO2007109080A2 (en)	2006-03-16	2007-09-27	Vertex Pharmaceuticals Incorporated	Deuterated hepatitis c protease inhibitors
WO2007109604A2 (en) *	2006-03-20	2007-09-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions
BRPI0708957A2 (pt) *	2006-03-20	2011-06-28	Vertex Pharma	composições farmacêuticas
WO2007120595A2 (en) *	2006-04-11	2007-10-25	Novartis Ag	Amines for the treatment of hcv
WO2007133865A2 (en)	2006-04-11	2007-11-22	Novartis Ag	Hcv/hiv inhibitors an their uses
MX2009006806A (es) *	2006-12-22	2009-08-27	Vertex Pharma	Secado por rocio fluidizado.
WO2008074035A1 (en) *	2006-12-27	2008-06-19	Abbott Laboratories	Hcv protease inhibitors and uses thereof
JP2010519312A (ja) *	2007-02-23	2010-06-03	アベラファーマシューティカルズ，インコーポレイテッド	薬学的製剤
EP2463285A1 (en) *	2007-02-27	2012-06-13	Vertex Pharmaceuticals Inc.	Co-crystals and pharmaceutical compositions comprising the same
WO2008106058A2 (en) *	2007-02-27	2008-09-04	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
DK2305263T3 (da) *	2007-06-07	2012-10-22	Novartis Ag	Stabiliserede amorfe former af imatinibmesylat
CN101835774B (zh) *	2007-08-30	2014-09-17	弗特克斯药品有限公司	共晶体和包含该共晶体的药物组合物
JP5149585B2 (ja) *	2007-10-02	2013-02-20	浜松ホトニクス株式会社	微粒子分散液製造方法
JP5161528B2 (ja) *	2007-10-02	2013-03-13	浜松ホトニクス株式会社	パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
CN104016970A (zh)	2007-10-10	2014-09-03	诺华股份有限公司	螺环吡咯烷类与其对抗hcv和hiv感染的应用
CL2008003092A1 (es) *	2007-10-19	2009-11-27	Abbott Gmbh & Co Kg	Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
WO2009061395A2 (en) *	2007-11-05	2009-05-14	Vertex Pharmaceuticals Incorporated	Hcv combination therapies
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
KR20110074870A (ko) *	2008-09-24	2011-07-04	버텍스 파마슈티칼스 인코포레이티드	간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법
EP2396028A2 (en)	2009-02-12	2011-12-21	Vertex Pharmceuticals Incorporated	Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
EA022924B1 (ru)	2009-04-03	2016-03-31	Ф.Хоффманн-Ля Рош Аг	ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
EP2459211A1 (en)	2009-07-31	2012-06-06	Medtronic, Inc.	Continuous subcutaneous administration of interferon- to hepatitis c infected patients
BR112012021556A2 (pt) *	2010-02-25	2017-03-21	Ver Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patiëntenzorg	processo para a preparação de peptídeos prolila substituídos e peptidomiméticos similares
TW201208704A (en)	2010-07-14	2012-03-01	Vertex Pharma	Palatable pharmaceutical composition
WO2012109646A1 (en)	2011-02-11	2012-08-16	Vertex Pharmaceuticals Incorporated	Treatment of hcv in hiv infection patients
AU2012225459A1 (en) *	2011-03-08	2013-10-10	Zalicus Pharmaceuticals Ltd.	Solid dispersion formulations and methods of use thereof
US8409560B2 (en)	2011-03-08	2013-04-02	Zalicus Pharmaceuticals Ltd.	Solid dispersion formulations and methods of use thereof
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
AU2013201532B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
EA201490837A1 (ru)	2011-10-21	2014-11-28	Эббви Инк.	Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
JP5781706B2 (ja) *	2011-12-29	2015-09-24	アッヴィ・アイルランド・アンリミテッド・カンパニー	Ｈｃｖ阻害剤を含む固体組成物
WO2013116339A1 (en)	2012-01-31	2013-08-08	Vertex Pharmaceuticals Incorporated	High potency formulations of vx-950
CN109966264A (zh)	2012-02-27	2019-07-05	沃泰克斯药物股份有限公司	药物组合物及其施用
ITMI20120608A1 (it)	2012-04-13	2013-10-14	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
WO2013178031A1 (en) *	2012-06-01	2013-12-05	Sunshine Lake Pharma Co., Ltd.	New forms of telaprevir and preparation methods thereof
US20160039871A1 (en) *	2012-12-21	2016-02-11	Sandoz Ag	Novel forms of telaprevir
MY172166A (en)	2013-01-31	2019-11-15	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
KR20150129005A (ko)	2013-03-15	2015-11-18	베링거 인겔하임 인터내셔날 게엠베하	무정형 상태의 hcv 억제제의 고체 경구 투여 제형
SG11201600919UA (en)	2013-08-27	2016-03-30	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110193013B (zh) *	2019-07-02	2022-02-08	力品药业(厦门)股份有限公司	一种去乙酰真菌环氧乙酯固体分散体及其制备方法
KR20250018514A (ko) *	2022-05-16	2025-02-06	데이 원 바이오파마슈티칼즈, 인크.	범-raf 키나제 억제제의 경구 액체 현탁액
WO2024080308A1 (ja) *	2022-10-12	2024-04-18	中外製薬株式会社	ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9109506D0 (en) *	1991-05-02	1991-06-26	Wellcome Found	Therapeutic nucleosides
TW487582B (en) *	1995-08-11	2002-05-21	Nissan Chemical Ind Ltd	Method for converting sparingly water-soluble medical substance to amorphous state
US6054472A (en) *	1996-04-23	2000-04-25	Vertex Pharmaceuticals, Incorporated	Inhibitors of IMPDH enzyme
JPH107558A (ja) *	1996-06-19	1998-01-13	Eisai Co Ltd	溶解性改善製剤
EP0901786B1 (en) *	1997-08-11	2007-06-13	Pfizer Products Inc.	Solid pharmaceutical dispersions with enhanced bioavailability
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
ATE400251T1 (de) *	1999-02-09	2008-07-15	Pfizer Prod Inc	Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
UY26615A1 (es) *	2000-03-16	2001-10-25	Pfizer Prod Inc	Inhibidor de la glucogeno fosforilasa.
US6777400B2 (en) *	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
SV2003000617A (es) *	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB0102342D0 (en) *	2001-01-30	2001-03-14	Smithkline Beecham Plc	Pharmaceutical formulation
US6627760B1 (en) *	2001-06-25	2003-09-30	Astrazeneca Ab	Amorphous compound
HUP0501067A2 (en) *	2001-11-14	2006-02-28	Teva Pharma	Amorphous and crystalline forms of losartan potassium and process for their preparation
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6642204B2 (en) *	2002-02-01	2003-11-04	Boehringer Ingelheim International Gmbh	Hepatitis C inhibitor tri-peptides
US6828301B2 (en) *	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
JP2007509950A (ja) *	2003-10-27	2007-04-19	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Ｈｃｖ処置の組合せ剤
TW201424733A (zh) *	2004-10-29	2014-07-01	Vertex Pharma	劑量型式

2005
- 2005-06-08 BR BRPI0511900-6A patent/BRPI0511900A/pt not_active IP Right Cessation
- 2005-06-08 MX MXPA06014253A patent/MXPA06014253A/es not_active Application Discontinuation
- 2005-06-08 AR ARP050102345A patent/AR049297A1/es unknown
- 2005-06-08 CA CA002569310A patent/CA2569310A1/en not_active Abandoned
- 2005-06-08 ZA ZA200700030A patent/ZA200700030B/xx unknown
- 2005-06-08 WO PCT/US2005/019929 patent/WO2005123076A2/en not_active Ceased
- 2005-06-08 RU RU2006147247/15A patent/RU2373923C2/ru not_active IP Right Cessation
- 2005-06-08 SG SG200903859-7A patent/SG153800A1/en unknown
- 2005-06-08 JP JP2007527639A patent/JP2008501802A/ja active Pending
- 2005-06-08 KR KR1020127008036A patent/KR20120039763A/ko not_active Ceased
- 2005-06-08 US US11/147,524 patent/US20060089385A1/en not_active Abandoned
- 2005-06-08 NZ NZ588471A patent/NZ588471A/en not_active IP Right Cessation
- 2005-06-08 AU AU2005253957A patent/AU2005253957B2/en not_active Ceased
- 2005-06-08 CN CNA200580024232XA patent/CN1988885A/zh active Pending
- 2005-06-08 CN CN2011103013245A patent/CN102512372A/zh active Pending
- 2005-06-08 TW TW094118847A patent/TWI389688B/zh not_active IP Right Cessation
- 2005-06-08 KR KR1020077000437A patent/KR101370580B1/ko not_active Expired - Fee Related
- 2005-06-08 EP EP05757623A patent/EP1765283A4/en not_active Withdrawn
2006
- 2006-12-04 IL IL179809A patent/IL179809A/en not_active IP Right Cessation
2007
- 2007-01-08 NO NO20070130A patent/NO20070130L/no not_active Application Discontinuation
2008
- 2008-03-26 ZA ZA200802676A patent/ZA200802676B/en unknown
2012
- 2012-01-05 JP JP2012000814A patent/JP5337262B2/ja not_active Expired - Fee Related
- 2012-09-20 IL IL222003A patent/IL222003A0/en unknown
2013
- 2013-04-12 US US13/861,791 patent/US20130274180A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005123076A2 (en)	2005-12-29
AU2005253957A1 (en)	2005-12-29
JP5337262B2 (ja)	2013-11-06
ZA200802676B (en)	2009-12-30
MXPA06014253A (es)	2007-07-13
EP1765283A2 (en)	2007-03-28
TWI389688B (zh)	2013-03-21
IL179809A0 (en)	2007-05-15
US20130274180A1 (en)	2013-10-17
TW200608975A (en)	2006-03-16
RU2373923C2 (ru)	2009-11-27
WO2005123076A3 (en)	2006-06-15
ZA200700030B (en)	2009-06-24
KR20120039763A (ko)	2012-04-25
US20060089385A1 (en)	2006-04-27
KR101370580B1 (ko)	2014-03-06
CA2569310A1 (en)	2005-12-29
JP2008501802A (ja)	2008-01-24
JP2012067138A (ja)	2012-04-05
AR049297A1 (es)	2006-07-12
EP1765283A4 (en)	2012-11-28
IL179809A (en)	2012-10-31
SG153800A1 (en)	2009-07-29
NZ588471A (en)	2012-02-24
CN1988885A (zh)	2007-06-27
CN102512372A (zh)	2012-06-27
IL222003A0 (en)	2012-12-02
AU2005253957B2 (en)	2011-08-25
KR20070030270A (ko)	2007-03-15
NO20070130L (no)	2007-01-25
RU2006147247A (ru)	2008-07-20

Publication	Publication Date	Title
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
RU2398586C3 (ru)	2017-10-04	Фармацевтическая композиция
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
ITMI20041252A1 (it)	2004-09-22	Composizioni perfluoroelastomeriche
CY2014030I1 (el)	2020-05-29	Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP1788047A4 (en)	2011-12-21	WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0613033A2 (pt)	2016-11-29	composição oral
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
DK1957073T3 (da)	2014-05-12	Lægemiddel
DE602005016978D1 (de)	2009-11-12	Quecksilberfreisetzende Zusammensetzungen
DK2033629T3 (da)	2013-02-04	Fast farmaceutisk sammensætning omfattende valsartan
DE502006006590D1 (de)	2010-05-12	Biozide zusammensetzungen
DE602005017191D1 (de)	2009-11-26	Geruchsreduzierte waschstück-zusammensetzung
EP1937255A4 (en)	2013-06-26	PHARMACEUTICAL COMPOSITION
FR2871686B1 (fr)	2008-02-29	Composition anti-decoloration
EP1862184A4 (en)	2012-12-19	PHARMACEUTICAL COMPOSITION
ITMI20041447A1 (it)	2004-10-20	Composizione farmaceutica comprendente gabapentina

Legal Events

Date	Code	Title	Description
2015-06-16	B25A	Requested transfer of rights approved	Owner name: JANSSEN PHARMACEUTICA NV (BE)
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.